Incidence of drug-induced hypersensitivity syndrome associated with levetiracetam and clobazam is likely underreported

Ann Allergy Asthma Immunol. 2024 May;132(5):652-653. doi: 10.1016/j.anai.2024.02.003. Epub 2024 Feb 10.

Authors

Nikhita R Kichili¹, Alyssa Hansen², Dheeraj Kagithala³, Ayezel Munoz Gonzalez⁴, Michael Wilkerson⁴

Affiliations

¹ John Sealy School of Medicine, University of Texas Medical Branch, Galveston, Texas.
² Department of Dermatology, University of Texas Medical Branch, Galveston, Texas. Electronic address: achansen@utmb.edu.
³ Wayne State University School of Medicine, Detroit, Michigan.
⁴ Department of Dermatology, University of Texas Medical Branch, Galveston, Texas.

PMID: 38346472
DOI: 10.1016/j.anai.2024.02.003

No abstract available

Publication types

Letter

MeSH terms

Adult
Anticonvulsants* / adverse effects
Benzodiazepines / adverse effects
Clobazam* / adverse effects
Drug Hypersensitivity / epidemiology
Drug Hypersensitivity Syndrome* / diagnosis
Drug Hypersensitivity Syndrome* / epidemiology
Drug Hypersensitivity Syndrome* / etiology
Female
Humans
Incidence
Levetiracetam* / adverse effects
Levetiracetam* / therapeutic use
Male
Middle Aged
Piracetam / adverse effects
Piracetam / analogs & derivatives
Piracetam / therapeutic use

Substances

Levetiracetam
Clobazam
Anticonvulsants
Benzodiazepines
Piracetam